Michael Belloy at Washington University in St. Louis noted that the findings could help distinguish between genes that directly affect pathology, and those that instead help maintain cognition in the ...
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases ...
This important study provides solid in-vivo evidence that CCR4 regulates the early inflammatory response during atherosclerotic plaque formation. The authors propose that altered T-cell response plays ...